The level of GAPDH measured with the sandwich-type ELISA immunoassay was low in samples from MCI and ‘mild AD’ patients, and progressively increased with the AD stage, reaching 12.5 ± 1.5 ng/mL in the ‘severe AD’ group (Fig. 1B). This evidence concerns the gene GAPDH and Alzheimer disease.